Table. 1.

Baseline characteristics and clinical outcomes of liver transplantation recipients

Variable Total DDLT LDLT P-value
Number 31 13 18
Age (yr) 55.16±7.41 55.92±7.40 52.11±13.94 0.378
Sex 0.129
Male 21 (67.7) 11 (84.6) 10 (55.5)
Female 10 (32.3) 2 (15.4) 8 (44.5)
BMI (kg/m2) 23.84±3.20 24.09±4.02 23.66±2.57 0.718
PMI (cm2/m2) 12.23±3.81 11.93±4.20 12.44±3.62 0.715
HCC 10 (32.3) 5 (38.5) 5 (27.8) 0.701
Blood chemistry
Platelet (x103/μL) 64.29±34.57 50.15±30.26 74.50±34.63 0.051
PT-INR 2.63±1.71 3.41±2.19 2.06±1.00 0.028
Total bilirubin (mg/dL) 14.48±13.41 19.00±11.50 11.22±14.04 0.112
Cr (mg/dL) 0.90±0.46 1.20±0.55 0.69±0.20 0.006
Albumin (g/dL) 3.45±0.58 3.25±0.6 3.59±0.55 0.111
Ammonia (μMol/L) 65.13±37.15 58.92±19.40 69.61±46.03 0.439
MELD baseline 21.42±11.91 29.46±11.65 15.61±8.33 0.001
Post-LT care
ICU stay (day) 6.87±4.23 8.77±3.27 5.50±4.38 0.031
Mechanical ventilation (day) 2.23±1.45 2.92±1.26 1.72±1.41 0.020
Post-LT enteral nutrition start (day) 4.07±2.38 4.77±2.01 3.56±2.55 0.165
Enteral nutrition
Post-LT 0.016
<25 6 (19.4) 6 (45.2) 0
25–50 15 (48.4) 4 (30.8) 11 (61.1)
50–75 8 (25.8) 3 (23.1) 5 (27.8)
>75 2 (6.5) 0 2 (11.1)
Post-LT 0.287
Poor 7 (22.6) 4 (30.8) 3 (16.7)
Moderate 17 (54.8) 7 (53.8) 10 (55.6)
Good 7 (22.6) 2 (15.4) 5 (27.8)
Clinical outcome
Readmission due to infection 4 (12.9) 3 (23.1) 1 (5.6) 0.284

Values are presented as mean±standard deviation or number (%).

DDLT, deceased donor liver transplantation; LDLT, living donor liver transplantation; BMI, body mass index; PMI, psoas-muscle index; HCC, hepatocellular carcinoma; PT, prothrombin time; INR, international normalized ratio; Cr, creatinine; MELD, Model for End-Stage Liver Disease; LT, liver transplantation; ICU, intensive care unit.

Korean J Transplant 2020;34:38~46 https://doi.org/10.4285/kjt.2020.34.1.38
© Korean Journal of Transplantation